-
今开：--
昨收：--
-
今日区间：--
52周区间：--
-
成交量：--
成交额：--
-
市 值：--
市盈率：--
-
振幅：
每股收益：
成交量
董事会
- Wei Cao
- Wei Cao is the founder of Gracell Biotechnologies (Shanghai) Co., Ltd. (founded in 2017) and Gracell Biotechnologies, Inc. (founded in 2017). He is currently the Chief Executive Officer at Gracell Biotechnologies (HK) Ltd., Gracell Biopharmaceuticals, Inc., Suzhou Gracell Biotechnologies Co., Ltd., and Zephyrm Bioscience Ltd. (as an Independent Non-Executive Director starting in 2024). Dr. Cao previously worked as a Director at AbelZeta Pharma, Inc. from 2010 to 2016 and as the President, Chief Operating Officer & Director at Cellular Biomedicine Group Ltd. from 2010 to 2013. He holds a doctorate degree from Medical College of Virginia and Harvard Medical School, and an undergraduate degree from Zhongshan Hospital Fudan University.
-
- Kin Ping Lee
- Kin Ping Lee currently serves as Independent Director at Gracell Biotechnologies, Inc. since 2021 and as Chief Executive & Responsible Officer at Lotus Asset Management Ltd. Former roles include Chief Executive Officer-Asset Management at Sun Hung Kai & Co. Ltd., Chief Executive Officer at Sun Hung Kai Wealth Management Ltd., Chief Executive Officer at Bright Fund Management Ltd., Chief Executive Officer at Bright Fund Management LTD (Private Equity) in 2010, Chairman-Hong Kong Branch at The Alternative Investment Mgmt Association Ltd. (Singapore) from 2004 to 2012, Managing Director at FrontPoint Management (Hong Kong) Ltd., Executive Director-Investment Management Division at Goldman Sachs (Asia) LLC from 1997 to 2000, Independent Non-Executive Director at Goldstream Investment Ltd. from 2019 to 2025, and Chief Financial Officer at OrbusNeich Medical KK from 2012 to 2017. Education includes an undergraduate degree from the University of Pennsylvania, conferred in 1991.
-
- Guo Tong Xu
- Guo Tong Xu is an Independent Director at Zhejiang Shapuaisi Pharmaceutical Co. Ltd., Guangzheng Eye Hospital Group Co., Ltd., PharmaLegacy Laboratories (Shanghai) Co., Ltd., Gracell Biotechnologies, Inc., and Yunnan Biovalley Pharmaceutical Co., Ltd. He is also a Professor at Tongji University. Previously, he served as an Independent Director at AbelZeta Pharma, Inc. and as the Director-Stem Cell Bank at Temple University School of Medicine. Dr. Xu obtained his undergraduate degree from Harbin Medical University and holds doctorate degrees from the University of North Texas Health Science Center, Chinese Academy of Medical Sciences, and Peking Union Medical College.
-
- Guo Wei Wang
- Guo Wei Wang is the founder of First Genetic Trust, Inc. Current positions include Chairman at Sirius Therapeutics starting 2025; Director roles at MJ Group Enterprises Ltd., Medicalsystem Co., Ltd., Shanghai Upper Bio-Tech Pharma Co., Ltd., Laekna Therapeutics (Shanghai) Co., Ltd., Sichuan Credit Pharmaceutical Co., Ltd. (since 2020), Gracell Biotechnologies, Inc. (since 2020), Ming Yu Pharmaceutical Ltd. starting 2025, Good Doctor Cloud Healthcare & Technology Group Co. Ltd. (since 2020), and Frontera Therapeutics starting 2025; Non-Executive Director at AK Medical Holdings Ltd. since 2016, Shanghai NewMed Medical Co., Ltd. since 2020, Sichuan Biokin Pharmaceutical Co., Ltd. since 2017, Edding Group Co., Ltd. since 2020, Gaush Meditech Ltd. since 2021, Laekna, Inc. since 2022; Partner and Senior Managing Director at Orbimed Advisors Private Equity; and Director at Sichuan Credit Pharmaceutical Co., Ltd. since 2020. Former roles include Director at Response Biomedical Corp. from 2011 to 2015, Director at StemCyte, Inc., Managing Director at AVIVA Biosciences Corp., Managing Director at WI Harper Group, Inc., Director-Healthcare Investment at WI Harper Group, Inc. (China) from 2006 to 2011, Director at Edan Instruments, Inc., Bonovo Orthopedics, Inc., Amoy Diagnostics Co., Ltd., Non-Executive Director at EC Healthcare from 2018 to 2020, Director at Suzhou MedicalSystem Technology Co., Ltd. from 2012 to 2019, Director at Beijing Chemclin Biotech Co., Ltd., Director at Sinovac Biotech Ltd. in 2025, Principal at Bristol Myers Squibb Co., and Head-Business Development at Siemens Medical Solutions USA, Inc. Education includes a doctorate from California Institute of Technology conferred in 1995 and a doctorate from Peking University Health Science Center conferred in 1986.
-